

**WEDNESDAY 20<sup>TH</sup> APRIL, 2016**

8:00am - 9:00am	<b>Registration</b>	
8:50am- 10:00am	<b>SESSION ONE</b>	
8:50am	<b>Welcome</b> <b>Rajiv Khanna</b>	
9:00am	Opening Plenary Lecture <b>Professor Dario Campana</b> Cellular immunotherapy of cancer	<b>abs#001</b>
9:30am	<b>Keynote Lecture</b> <b>Professor Michael Good</b> Modelling immunity to group A streptococcus (GAS) reveals that a failure of strain-specific immune induction may underlie the epidemic of streptococcal pyoderma: overcoming immune resistance through vaccination	<b>abs#002</b>
10:00am-10:30am	<b>Morning Tea</b>	
10:30am-12:00pm	<b>SESSION TWO: Advances in Immuno-oncology</b> <b>Chair: Associate Professor Phil Darcy</b>	
	<b>Professor Evan Newall</b> Identifying and profiling tumor specific T cells using mass cytometry and highly multiplexed peptide-MHC tetramer staining	<b>abs#003</b>
	<b>Dr. Marc Pellegrini</b> A vulnerable liaison - TNF, host cell IAPs and our pathogens	<b>abs#004</b>
	<b>Dr. Michele Teng</b> Superior power of neoadjuvant immunotherapy to eradicate metastatic disease	<b>abs#005</b>
11:30am	<b><u>Discussion Forum – Advances in Immuno-oncology</u></b> <b>Chair: Associate Professor Phil Darcy</b> <b>Dr. Evan Newall, Dr. Marc Pellegrini and Dr. Michele Teng</b>	
12:00pm - 1:00pm	<b>Lunch</b>	
1:00pm - 2:00pm	<b>SESSION THREE: CAR T cells – Preclinical Development to Clinical Application</b> <b>Chair: Professor Gabrielle Belz</b> <b>Dr. Siok Tey</b> Safety Switches for T Cells	<b>abs#007</b>

**A/Prof. Phil Darcy**

Enhancing adoptive cellular therapy by targeting tumor-induced immunosuppression

**abs#008**

**Mariusz Skwarczynski**

Liposomes in intranasal and oral delivery of lipopeptide-based vaccines

**abs#009**

2:00pm - 3:00pm

**SESSION FOUR: Clinical Trial Designs for Immunotherapy and Novel Vaccines**

**Chair: Dr Ian Barr**

**Professor Ranjeny Thomas**

Antigen-specific tolerizing immunotherapy for rheumatoid arthritis: towards precision medicine

**abs#010**

**Dr. Suzanne Elliott**

Critical Design Elements for a Successful Vaccine Trial

**abs#011**

**Mehfuz Zaman**

Development of a liposomal mucosal vaccine delivery system against an upper respiratory tract pathogen (Group A Streptococcus)

**abs#012**

3:00pm - 3:25pm

**Afternoon Tea**

3:25pm - 4:10pm

**SESSION FIVE: Young Investigators Abstract Presentations**

**Chair: Dr Michelle Wykes**

**Ms. Nicola MacLennan**

Lipovaxin, a versatile liposomal vaccine delivery platform, combining antigens with immune-stimulatory particles for improved immune responses

**abs#013**

**Dr Stacy Scott**

New Zealand regulation of medicines that contain genetically modified organisms

**abs#014**

**Ms. Louise A Carolan**

Characterisation of the localised immune response in the respiratory tract of ferrets following infection with influenza A and B viruses

**abs#015**

4:10pm - 5:20pm

**SESSION SIX: Innate Immune Response and Vaccine Design**

**Chair: Dr Christian Engwerda**

**Dr. Florent Ginhoux**

Dendritic Cell and Macrophage Ontogeny

**abs#016**

**Associate Professor Michele Grimaldeston**

Novel approaches to control mast cell function in allergic inflammation

**abs#017**

**Mr Branka Grubor-Bauk**

New life from dead cells: A novel necrotic cell vaccine, encoding the hepatitis C virus NS3 protein, induces superior cell mediated immune responses, compared to those of a live cell vaccine.

**abs#018**

**Ms. Victoria Ozberk**

Development of a novel intranasal vaccine to prevent upper respiratory tract infection by group A streptococcus

**abs#019**

**Noushin Jaberolansar**

Design and efficacy evaluation of peptide-based vaccine against RSV

**abs#046**

5:35pm - 7:00pm

**Welcome Reception**

**THURSDAY 21<sup>st</sup> APRIL, 2016**

8:50am - 10:00am

**SESSION SEVEN: Adoptive Immunotherapy**

**Chair: Professor Dario Campana**

8:50am

**Plenary Lecture II**

**Professor Geoff Hill**

Novel cytokine and cellular therapy in transplantation

**abs#020**

9:20am

**Discussion Forum: Adoptive Immunotherapy**

**Chair: Professor Rajiv Khanna**

**Professor Geoff Hill, Associate Professor Phil Darcy and Professor Dario Campana**

10:00am-10:30am

**Morning Tea**

10:30am-12:00pm

**SESSION EIGHT: Effector Memory Immune Cells and Vaccination**

**Chair: Associate Professor Kristen Radford**

**Professor Steve Turner**

Genome wide mapping of histone modifications identifies novel regulatory elements that underpin virus-specific CD8+ T cell differentiation

**abs#022**

**Dr. Tonia Woodberry**

Dendritic cells and Plasmodium: early infection compromises CD1c myeloid but not plasmacytoid dendritic cells

**abs#023**

**Ms. Susanna Ng**

Characterising the role of group 1 innate lymphoid cells during malaria

**abs#024**

11:40pm - 1:00pm

**Lunch**

1:00pm - 2:50pm

**SESSION NINE: Therapeutic Antibodies**

**Chair: Dr Michele Teng**

**Dr. Kristen Radford**

Targeting human Clec9A+ dendritic cells for immunotherapy

**abs#025**

**Dr. Michelle Wykes**

PD-L2 is crucial for establishing effective CD4+ Th1 immunity against malaria+

**abs#026**

**Ms. Marcela Montes do Oca**

Type I interferons are potent immune regulators in humans with blood-stage Plasmodium falciparum infection

**abs#027**

**Mr. Branka Grubor-Bauk**

Intradermal delivery of DNA encoding HCV NS3 and perforin elicits robust cell mediated immunity in mice and pigs

**abs#028**

**Mr. Nicholas Ede**

Development of a clinical-ready polyclonal anti-HER-2/neu vaccine against breast and gastric cancer

**abs#029**

**Professor Eric Gowans**

A novel replicating recombinant human rhinovirus vaccine that generates mucosal and systemic immunity to HIV-1 Gag & Tat

**abs#030**

2:50pm - 3:20pm

**Afternoon Tea**

**SESSION TEN: Emerging Infectious Diseases - Challenges and Solutions**

**Chair: Dr Florent Ginhoux**

**Professor Andreas Suhrbier**

Horse immunoglobulin for treatment of Ebola virus infections

**abs#031**

**Ms. Heidi A Peck**

Evaluation of influenza B viruses for use in cell-based quadrivalent influenza vaccines

**abs#032**

**Ms. Champa Ratnatunga**

Multi-parametric immunoprofiling in Mycobacterium abscessus infection reveals distinct T cell exhaustion and dysfunction patterns in at-risk patient groups

**abs#033**

4:10pm - 5:00pm

**SESSION ELEVEN: Commercialisation of Vaccine and Immunotherapeutic Drugs**

**Chair: Professor Andreas Suhrbier**

**Dr. Goslik Schepers**

Commercialising I-O technologies

**abs#034**

**Dr. Neil Finlayson**

Commercialisation of Vaccine and Immunotherapeutic Drugs

**abs#035**

5:00pm - 6:00pm

**Poster and Networking Function**

7:00pm - 10:00pm

**Conference Dinner**

**FRIDAY 22<sup>nd</sup> APRIL, 2016**

8:50am-9:40am

**SESSION TWELVE – Cellular Immune Regulation and Immunotherapy**

**Chair: Professor Ranjeny Thomas**

**Plenary Lecture III**

**Professor Barbara Fazekas de St Groth**

Selective Treg reconstitution during lymphopenia normalizes DC costimulation and prevents graft-versus-host disease

**abs#036**

**Keynote Lecture IV**

**Professor Jamie Rossjohn**

Immune sensing of vitamin B metabolites

**abs#037**

9:40am-10:50am

**SESSION THIRTEEN: Immunotherapeutics for Chronic Diseases**

**Chair: Professor Steve Turner**

**Dr. Laura Mackay**

Development and Function of Tissue-Resident Lymphocytes

**abs#039**

**Dr. John Miles**

Understanding and augmenting the human TCR/pMHC axis

**abs#040**

**Dr Kok Fei Chan**

The structural basis underpinning polyclonal T-cell receptor recognition of an unusually long 13-mer peptide from tumor antigen NY-ESO-1 presented by HLA-B\*0702 and its implication in cancer vaccine design

**abs#041**

**Dr Manisha Pandey**

A combination vaccine strategy involving two synthetic peptides protects against superficial and deep tissue infection with hypervirulent group A streptococcus

**abs#042**

10:50am-11:40am

**Morning Tea**

11:40am-12:30pm

**SESSION FOURTEEN: Immunotherapy and Vaccine Development –  
Bench to Bedside**

**Chair: Professor Andreas Suhrbier**

**Professor Eric Reynolds**

A therapeutic vaccine for *Porphyromonas gingivalis*-mediated chronic disease

**abs#043**

**Dr Frédéric Triebel**

LAG 3: Validation of Next Generation Checkpoint Pathways

**abs#044**

**Dr. Bill Dougall**

Challenges and Considerations in Oncology Drug Development: Lessons from Denosumab

**abs#045**

12:40pm-12:45pm

**Closing Announcements and Best Poster and Oral Presentations**